Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORT-HER trial of 3 versus 12 months of trastuzumab in HER2-positive early breast cancer
2007-004326-25Phase 3Completed
- Sponsor
- AOU Policlinico di Modena
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by AOU Policlinico di Modena. Primary endpoints: Overall survival and Disease-free survival. Started Nov 2007; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-004326-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004326-25.